Table 3.
Top diseases, functions and pathways involving predicted gene targets of miRNA altered with olanzapine treatment—integration analysis of miRNA and gene expression. (IPA core analyses; N = number of focus genes in function/term)
| Olanzapine | ||
|---|---|---|
| Diseases and disorders | p value range | N |
| Neurological disease | 1.76E−05 to 4.71E−02 | 24 |
| Developmental disorder | 9.81E−05 to 4.01E−02 | 21 |
| Cancer | 3.23E−04 to 4.87E−02 | 27 |
| Organismal injury and abnormalities | 9.62E−04 to 4.87E−02 | 10 |
| Haematological disease | 1.10E−03 to 3.78E−02 | 10 |
| Molecular and cellular functions | ||
| Cellular assembly and organization | 2.92E−04 to 4.87E−02 | 26 |
| Cell death | 7.52E−04 to 4.87E−02 | 14 |
| Gene expression | 1.37E−03 to 4.44E−02 | 25 |
| Cellular compromise | 1.42E−03 to 4.87E−02 | 10 |
| Cellular growth and proliferation | 1.57E−03 to 4.24E−02 | 27 |
| Physiological system development and function | ||
| Organismal functions | 6.53E−05 to 2.95E−02 | 13 |
| Tissue development | 4.98E−04 to 4.87E−02 | 47 |
| Nervous system development and function | 5.67E−04 to 4.87E−02 | 39 |
| Tissue morphology | 5.67E−04 to 4.75E−02 | 21 |
| Embryonic development | 5.90E−04 to 4.87E−02 | 34 |
| Canonical pathways | p value | Ratio |
| IL-8 signalling | 2.62E−04 | 8/172 |
| Gα12/13 signalling | 9.59E−04 | 6/117 |
| Axonal guidance signalling | 1.36E−03 | 11/398 |
| TR/RXR activation | 1.49E−03 | 5/87 |
| VEGF signalling | 1.57E−03 | 5/89 |